Natera, Inc.
Natera, Inc. (Nasdaq: NTRA) is a diagnostics company that applies proprietary molecular assays and bioinformatics to genetic testing in oncology, women’s health and organ health. Its products include Signatera, a personalized blood test for cancer residual disease and recurrence monitoring; Panorama, a non-invasive… From the company’s description.
In fiscal 2025, Natera, Inc. reported revenue of $2.31B, up 35.9% from fiscal 2024, and a net loss of $208.16M. Its operating margin was −13.4%, and operations generated $215.30M in cash. Over the twelve months to Jun 30, 2026, revenue was $2.71B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Natera, Inc. does
In the company’s own words
Natera, Inc. (Nasdaq: NTRA) is a diagnostics company that applies proprietary molecular assays and bioinformatics to genetic testing in oncology, women’s health and organ health. Its products include Signatera, a personalized blood test for cancer residual disease and recurrence monitoring; Panorama, a non-invasive prenatal screen; Horizon, a carrier screening test; and Prospera, which assesses rejection after kidney, heart and lung transplants. Other offerings include tumor profiling, hereditary cancer and single-gene screening, kidney disease testing, and Constellation, cloud software that lets partner laboratories run testing workflows and analyze results using Natera’s algorithms. Customers and users include healthcare providers, laboratories, researchers and biopharmaceutical companies; tests are sold directly in the United States and through laboratory and distribution partners internationally. Natera reports three medical areas of focus—oncology, women’s health and organ health—and processes tests in its own CLIA-certified laboratories. In 2025, revenue was $2.31 billion, and the company processed approximately 3.5 million tests. Its website is www.natera.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Health Services
- Headquarters
- AUSTIN, TX
- Fiscal year end
- December
- CIK
- 1604821
- SIC
- 8071
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Natera, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Natera, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Natera, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Natera, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Natera, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Natera, Inc.'s last four quarterly filings that the numbers alone won't show?”